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Abstract
Background: Chronic kidney disease-mineral and bone disorders (CKD-MBD) have been associated with poor
health outcomes, including diminished quality and length of life. Standard management for CKD-MBD includes
phosphate-restricted diet, active vitamin D, vitamin D analogs, and phosphate binders. Persistently elevated
parathyroid hormone (PTH) levels may require the addition of Cinacalcet hydrochloride (cinacalcet) which sensitizes
calcium receptors on the parathyroid glands. The objective of this systematic review is to compare the effect of
cinacalcet versus standard treatment in patients with CKD-MBD.
Methods/design: Data sources will include MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and Web
of Science from 1996 to June 2015. Teams of two reviewers will, independently and in duplicate, screen titles and
abstracts and potentially eligible full text reports to determine eligibility, and subsequently abstract data and assess risk
of bias in eligible trials. We will calculate the effect estimates (risk ratios or mean differences) and 95 % confidence
intervals, as well as statistical measures of variability in results across studies using random effect models for
patient-important and intermediate outcomes. We will use the GRADE (Grading of Recommendations, Assessment,
Development and Evaluation) approach to rate the quality of evidence about estimates of effect on an
outcome-by-outcome basis. We will present our results with a GRADE summary table.
Discussion: Our review will explore the effect of cinacalcet versus standard treatment in patients with CKD-MBD. The
results of this systematic review will help guide management of this patient population, and identify targets for future
research.
Systematic review registration: PROSPERO CRD42015020318http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42015020318.
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Background
Chronic kidney disease-mineral and bone disorder
(CKD-MBD) is a systematic condition defined by three
components: (1) extra skeletal calcifications; (2) abnormal
metabolism of serum calcium, phosphorus, parathyroid
hormone (PTH), and vitamin D; and (3) abnormal bone
metabolism, including bone turnover, mineralization, lin-
ear growth, and reduced strength [1]. CKD-MBD is also
associated with extravascular calcifications, increased
cardiovascular events, and mortality [1]. The pathogenesis
of CKD-MBD involves receptor level problems, including
vitamin D receptors and calcium-sensing receptors [2, 3].
Abnormal serum calcium, phosphorus, PTH, and vitamin
D levels also contribute to the development of the disease
process [2–4].
Parathyroid gland hyperplasia is a common finding in
patients with CKD-MBD, and proliferation in parathyroid
cells leads to increase in parathyroid gland secretion. This
leads to secondary hyperparathyroidism (SHPT) which is
associated with elevated serum PTH levels [5]. A consen-
sus exists regarding the need for CKD-MBD treatment to
maintain guideline recommended targets for calcium,
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phosphorus, and PTH in the presumption that meeting
these targets will improve quality and quantity of life
[3, 6–8].
In the management of CKD-MBD, recommendations
suggest that patients should, in addition to phosphate-
restricted diet, receive active vitamin D and phosphate
binders [3, 6, 9]. Medical management of persistent
elevated PTH requires the use of calcimimetic agents.
Cinacalcet hydrochloride (cinacalcet) is a second gen-
eration calcimimetic agent used to sensitize calcium
receptors on the parathyroid glands [10, 11]. This
leads to decreased PTH synthesis and secretion [10,
11]. Cinacalcet is a positive allosteric modulator that
interacts with non-calcium binding sites [2]. Although
this therapy has a very wide applicability, including
parathyroid cancers and primary and secondary
hyperparathyroidism, cost is a major drawback that
limits utilization [12].
In 2004, the US Food and Drug Administration ap-
proved cinacalcet for uncontrolled SHPT in CKD-MBD
patients. The medication is not recommended for pre-
dialysis patients because of the potential risks for severe
hypocalcemia and phosphate increase due to the low
PTH levels [6, 13, 14]. The total cost of cinacalcet per
patient with CKD-MBD ranges from $4000 to $23,500
per year in Canada.
CKD-MBD has been associated with increased mortal-
ity, and reduced bone and cardiovascular health [15].
Prior systematic reviews have found that cinacalcet treat-
ment reduces the rate of parathyroidectomy, fracture,
and hospitalization due to cardiovascular events [16, 17];
the effect on mortality has not been established [18–20].
However, prior reviews have not included trials pub-
lished after February 2013 and only included adult
CKD patients.
We will update search covering more databases and
the pediatric patient population with transparent quality
assessment of findings. The consequences of CKD-MBD
and pharmacokinetic and pharmacodynamic properties
of cinacalcet may differ between the adult and pediatric
patient populations. We will explore for a subgroup
effect on this basis (adult versus children) and, if the test
of interaction is significant, we will present results separ-
ately for these populations.
The objective of this systematic review is to evaluate
the impact of cinacalcet treatment as compared to
standard treatment alone or standard treatment plus
placebo in patients with CKD-MBD and uncontrolled
SHPT on patient-important outcomes, including
cardiovascular events, fractures, parathyroidectomy,
symptomatic hypotension, cardiovascular mortality,
all-cause mortality, and intermediate outcomes—a-
chieving Kidney Disease Outcome Quality Initiative
targets (K/DOQI).
Methods/design
Data sources and search strategy
We will search the MEDLINE, EMBASE, and Cochrane
Register of Controlled Trials and Web of Science data-
bases from 1996 until June 2015 without any restric-
tions. We will use controlled vocabulary and text words
to search all databases. We will scan the bibliographies
of all prior systematic reviews and meta-analyses as well
as all eligible primary studies for additional relevant arti-
cles. We will search for conference proceedings from
2010 to 2015 using the Web of Science and abstracts
presented at recent annual meetings (the American Soci-
ety of Nephrology, National Kidney Foundation, Inter-
national Society of Nephrology and European Renal
Association-European Dialysis and Transplant Associ-
ation). Please refer to Table 1 for the full search strategy.
Eligibility criteria
We will limit the studies included in this review to RCTs
evaluating the effectiveness and safety of cinacalcet for
the treatment of secondary HPT. The comparator will
be the standard therapy alone or standard therapy plus
placebo. The standard therapy includes phosphate
binders and/or active vitamin D. This review will explore
the effectiveness of cinacalcet treatment on the following
outcomes: cardiovascular events, fractures, parathyroidec-
tomy, symptomatic hypotension, cardiovascular mortality,
all-cause mortality, end-of-treatment alkaline phosphatase,
end-of-treatment PTH levels (any measure), end-of-
treatment serum calcium concentrations (mg/dL or
mmol/L), end-of-treatment serum phosphorus concentra-
tions (mg/dL or mmol/L), end-of-treatment calcium x
phosphorus product (mg2/dL2). We will not employ any
restrictions for age. We will not include studies that the
primary objective of which is to determine optimal dosing
of cinacalcet and economic evaluation of cinacalcet
treatment.
Study selection
Teams of two investigators will independently screen
each unique title and abstract that our literature search
identifies. If either reviewer identifies a citation as poten-
tially relevant, we will obtain the full text of the article.
Two reviewers will independently determine the eligibil-
ity of all studies that undergo full text evaluation. We
will measure the inter-rater agreement for full text eligi-
bility and assessment of the risk of bias using the kappa
statistic [21]. Values of kappa between 0.40 and 0.59
have been considered to reflect fair agreement, between
0.60 and 0.74 to reflect good agreement and ≥0.75 to
reflect excellent agreement [21]. Disagreements will be
resolved through discussion between the reviewers or
through adjudication with a third party if necessary.
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Table 1 Search strategy for the MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials databases
MEDLINE
Set History Comments
1 (((kidney* or nephro* or renal or home or peritoneal or intermittent or chronic or extracorporeal or
ambulatory) adj2 (haemodialys* or hemodialys* or dialys*)) or hemorenodialysis or hemodialyse or
CAPD).ti,ab.
Dialysis textword search Terms
2 renal dialysis/ or hemodialysis, home/ or peritoneal dialysis/ or peritoneal dialysis, continuous
ambulatory/
Dialysis subject Terms
3 renal insufficiency, chronic/ or kidney failure, chronic/ Chronic kidney disease subject terms
4 (((chronic or "end-stage" or "end stage") adj3 (kidney* or renal or nephro*) adj3 (insufficien* or
disease*)) or esrd).ti,ab.
Chronic kidney disease textword terms
5 frasier syndrome/ or ("frasier* syndrome*" or (frasier* adj2 syndrome*)).mp. Syndrome subject and textword terms
6 renalosteodystrophy/ or ((renal or kidney* or nephro*) adj2 (osteodystroph* or ricket*)).mp. Chronic kidney disease subject or textword
Terms
7 azotemia/ or azotemi*.mp. Azotemia subject or textword Terms
8 uremia/ or uremi*.mp. Uremia disease subject or textword Terms
9 or/1-1 Kidney disease terms
10 Calcimimetic Agents/ or (Calcimimetic* or amg073 or cinacalcet or "krn 1493" or krn1493 or
mimpara or parareg or regpara or sensipar).mp.
Cinacalcet subject and textword search
Terms
11 9 and 10 Base clinical set
12 controlled clinical trial.pt. or controlled clinical trials as topic/ or meta analysis.pt. ormeta analysis as
topic/ or multicentre study.pt. or multicenter studies as topic/ or randomized controlled trial.pt. or
randomized controlled trials as topic/ or pragmatic clinical trial.pt. or Pragmatic Clinical Trials as
Topic/ or ((preference or practical or pragmatic or "real world" or naturalistic) adj5 trial*).ti,ab. or
Comparative Effectiveness Research/ or ((comparative adj2 effectiveness) or (CER adj5 (research* or
method* or framework* or compari* or statement*))).ti,ab. or ((singl: or doubl: or tripl: or trebl:) and
(mask: or blind:)).ti,ab. or ((random: adj5 trial:) or rct or rcts).ti,ab.
Therapy Study design methodologies
13 11 and 12 FINAL Results
EMBASE
Set History Comments
1 (((kidney* or nephro* or renal or home or peritoneal or intermittent or chronic or extracorporeal or
ambulatory) adj2 (haemodialys* or hemodialys* or dialys*)) or hemorenodialysis or hemodialyse or
CAPD).ti,ab.
Dialysis textword search Terms
2 renal replacement therapy/ or continuous ambulatory peritoneal dialysis/ or continuous renal
replacement therapy/ or extended daily dialysis/ or hemodialysis/ or home dialysis/ or peritoneal
dialysis/
Dialysis subject Terms
3 kidney failure/ or chronic kidney failure/ Chronic kidney disease subject terms
4 (((chronic or "end-stage" or "end stage") adj3 (kidney* or renal or nephro*) adj3 (insufficien* or
disease*)) or esrd).ti,ab.
Chronic kidney disease textword terms
5 frasier syndrome/ or ("frasier* syndrome*" or (frasier* adj2 syndrome*)).mp. Syndrome subject and textword terms
6 renalosteodystrophy/ or ((renal or kidney* or nephro*) adj2 (osteodystroph* or ricket*)).mp. (7537) Chronic kidney disease subject or textword
Terms
7 azotemia/ or azotemi*.mp. Azotemia subject or textword Terms
8 uremia/ or uremi*.mp. Uremia disease subject or textword Terms
9 Or/1-8 Kidney disease terms
10 Calcimimetic Agent/ or cinacalcet/ or (Calcimimetic* or amg073 or cinacalcet or "krn 1493" or
krn1493 or mimpara or parareg or regpara or sensipar).mp.
Cinacalcet subject and textword search
Terms
11 9 and 10 Base clinical set
12 ct.fs. or controlled clinical trial.pt. or controlled clinical trial/ or meta analysis/ or multicenter study/
or randomized controlled trial.pt. or randomized controlled trial/ or double blind procedure/ or
single-blind procedure/ or triple blind procedure/ or ((preference or practical or pragmatic or "real
world" or naturalistic) adj5 trial*).ti,ab. or comparative effectiveness/ or ((comparative adj2
effectiveness) or (CER adj5 (research* or method* or framework* or compari* or statement*))).ti,ab. or
((random: adj5 trial:) or rct or rcts).ti,ab. or ((singl: or doubl: or tripl: or trebl:) and (mask: or blind:)).ti,ab.
Therapy Study design methodologies
13 11 and 12 FINAL Results
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Data abstraction
Using a standardized data collection form, two reviewers
will collect the following information from each study:
the author, date of publication, eligibility criteria, sum-
mary of baseline characteristics of the participants, num-
ber of participants in each arm at study onset and
completion, duration of the trial, and treatment effects,
including effectiveness and safety. We will resolve dis-
agreements by discussion.
Quality assessment of individual studies
A modified version of the Cochrane risk for bias tool
(http://distillercer.com/resources/) will be employed by
two independent reviewers in order to assess risk of bias
on an outcome-by-outcome basis for all eligible trials.
The assessment will include the following components:
adequacy of sequence generation, allocation sequence
concealment, level of blinding, incomplete outcome
data, loss to follow-up, and stopping early for benefit or
futility [22]. Reviewers will input response options of
“definitely yes”, “probably yes”, “probably no”, and “defin-
itely no” for each of the domains, with definitely yes and
probably yes ultimately assigned low risk of bias and def-
initely no and probably no assigned high risk of bias [23].
Reviewers will resolve disagreements by discussion, and
one arbitrator will adjudicate unresolved disagreements.
We will use to assess the quality of evidence for each
outcome using the GRADE (Grading of Recommenda-
tions, Assessment, Development and Evaluation) rating
system [24]. In the GRADE system of rating quality of
evidence for each outcome, randomized trials begin as
high quality evidence, but may be rated down by one or
more of five categories of limitations [25]. We will use
the GRADE methodology to rate certainty in effect esti-
mates and quality of evidence for each outcome as high,
moderate, low, or very low [25]. We will use the detailed
GRADE guidance to assess the overall risk of bias, im-
precision, inconsistency, indirectness, and publication
bias and summarize results with a GRADE summary
table [26]. The quality of evidence will be rated down, if
we determine risk of bias as well as large imprecision,
inconsistency, indirectness, and publication bias.
With the respect to precision, we will assess the optimal
information size (OIS; the number of patients generated
by a conventional sample size calculation for a single trial)
and the width of the 95 % CIs. GRADE guidance notes
that meta-analyses of small trials can provide evidence of
benefit with 95 % CIs that appear to convincingly exclude
no effect; however, the results of reviews of such studies
have often been subsequently refuted by larger trials [27,
28]. To address this potential concern in cases in which
our meta-analysis suggests benefit but the sample size is
less than the OIS, we will rate down imprecision. For the
purposes of calculating the OIS, we will assume, for binary
variables a relative risk reduction or increase (delta) of
25 %, an alpha of 0.05, and a beta of 0.20, and a median
baseline risk from the available studies. In addition, we
will examine the width of 95 % CIs and verify if 95 % CIs
overlap clinical decision thresholds for each outcome.
In addition to assessment of statistical heterogeneity,
the degree of proximity in point estimates and overlap
in 95 % confidence intervals (95% CI) will be examined
to assess consistency between studies. Differences in
methodology, study populations, outcomes, and quality
and quantity of interventions will be considered to
evaluate directness.
For each outcome, we will assess publication bias by
visually observing asymmetry of the funnel plot for each
outcome [29, 30]. We will follow published guidance
and construct funnel plots only for outcomes with ≥10
Table 1 Search strategy for the MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials databases (Continued)
EBM Reviews - Cochrane Central Register of Controlled Trials
Set History Comments
1 ((kidney* or nephro* or renal or home or peritoneal) adj2 (haemodialys* or hemodialys* or
dialys*)).ti,ab. or renal dialysis/ or hemodialysis, home/ or peritoneal dialysis/ or peritoneal dialysis,
continuous ambulatory/ or renal insufficiency, chronic/ or kidney failure, chronic/ or (((chronic or
"end-stage" or "end stage") adj3 (kidney* or renal or nephro*) adj3 (insufficien* or disease*)) or
esrd).ti,ab. or frasier syndrome/ or ("frasier* syndrome*" or (frasier* adj2 syndrome*)).mp. or renal
osteodystrophy/ or ((renal or kidney* or nephro*) adj2 (osteodystroph* or ricket*)).mp. or
azotemia/ or azotemi*.mp. or uremia/ or uremi*.mp. or (((kidney* or nephro* or renal or home or
peritoneal or intermittent or chronic or extracorporeal or ambulatory) adj2 (haemodialys* or
hemodialys* or dialys*)) or hemorenodialysis or hemodialyse or CAPD).ti,ab. or kidney failure/ or
chronic kidney failure/ or frasier syndrome/ or renal osteodystrophy/ or uremia/ or (((chronic or
"end-stage" or "end stage") adj3 (kidney* or renal or nephro*) adj3 (insufficien* or disease*)) or
esrd).ti,ab. or kidney failure/ or chronic kidney failure/ or frasier syndrome/ or ("frasier* syndrome*"
or (frasier* adj2 syndrome*)).mp. or renal osteodystrophy/ or ((renal or kidney* or nephro*) adj2
(osteodystroph* or ricket*)).mp. or azotemia/ or azotemi*.mp. or uremia/ or uremi*.mp.
Dialysis, chronic kidney diseases Subject or
textword search Terms
2 Calcimimetic Agent/ or cinacalcet/ or Calcimimetic Agents/ or (Calcimimetic* or amg073 or
cinacalcet or "krn 1493" or krn1493 or mimpara or parareg or regpara or sensipar).mp.
Cinacalcet subject and textword search
Terms
3 1 and 2 Base clinical set
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trials. Publication bias will be considered as unlikely un-
less the effect measure is asymmetrically distributed
around the pooled effect [29].
After considering these reasons for rating down, we
will judge the quality of evidence for each outcome as
follows: “high” quality of evidence (we are very confident
that the true effect lies close to that of the estimate of
the effect); “moderate” quality of evidence (we are moder-
ately confident in the effect estimate and the true effect is
likely to be close to the estimate of the effect, but there is
a possibility that it is substantially different); “low” quality
of evidence (our confidence in the effect estimate is lim-
ited and the true effect may be substantially different from
the estimate of the effect); and “very low” quality of evi-
dence (we have very little confidence in the effect estimate
and the true effect is likely to be substantially different
from the estimate of the effect) [25].
Data synthesis and statistical analysis
We will report descriptive statistics as proportions for
categorical variables and mean or medians for the con-
tinuous variables. We will calculate pooled risk ratios
(RRs) and the associated 95 % CI for each outcome
using random effects models by applying the Mantel-
Haenszel method. Absolute effects and the associated
95 % CI will be calculated by multiplying pooled RRs
and 95 % CI by the pooled control rate of outcomes.
Statistical heterogeneity will be assessed by the chi-square
test and I2 statistic. All data analyses will be performed
using Stata (StataCorp. 2013. Stata Statistical Software:
Release 13. College Station, TX: StataCorp LP).
Dealing with missing participant data for dichotomous
outcomes: sensitivity analyses
We will conduct a complete-case analysis for our primary
analysis and perform sensitivity analyses to address the
robustness of our findings with respect to the missing
data. We plan to use plausible worst-case scenario for the
missing trial-level data. The extent to which point esti-
mates and 95 % CIs differ in these sensitivity analyses will
determine whether we rate down for risk of bias [30, 31].
Assessment of heterogeneity and subgroup analyses
Our estimates of study heterogeneity will be informed
using the p value for the chi-square test for homogeneity
and the I2 statistic where 0–40 % may be unimportant
heterogeneity, 30–60 % moderate, 50–90 % substantial,
and 75–100 % considerable heterogeneity [32]. If the I2
statistic indicates a value >50 %, we will explore hetero-
geneity. We will employ random effects meta-regression
and include mean age, the mean baseline serum PTH
concentration, trial duration, and stages of CKD (dialysis
versus non-dialysis) in our univariate linear models.
We will employ subgroup analysis for the pediatric
and adult patient populations. If the interaction test sug-
gests a significant subgroup effect, we will report effect
estimates for each subgroup separately.
Presentation of results
We will present the results of our meta-analyses in an
evidence profile that will provide a succinct, easily di-
gestible presentation of quality of evidence, and magni-
tude of effects [26]. Our evidence profile will be
constructed to include the following elements: a meas-
ure of the typical burden of these outcomes (e.g., control
group, estimated risk; if appropriate studies are available,
we will use the baseline risk for population-based obser-
vational studies); a measure of the absolute risk differ-
ence between the risks with and without intervention;
the relative magnitude of effect; the numbers of partici-
pants and studies addressing these outcomes; a GRADE
rating of the overall confidence in estimate of effect for
each outcome and any reasons for rating down the con-
fidence [32].
Discussion
We expect to provide an objective assessment of effective-
ness and safety of cinacalcet in patients with CKD-MBD.
We will examine the impact of cinacalcet on patient-
important outcomes. In addition, we will explore the
quality of the existing evidence in both adult and
pediatric patient populations with CKD-MBD. This
will be the first systematic review that includes both
pediatric and adult CKD patient populations in the
assessment of cinacalcet and patient important outcomes
available in the literature. We will disseminate our results
in local meetings and in a peer-reviewed publication.
Strengths and limitations of this study
The methods of our proposed review are state of the art,
including explicit eligibility criteria, a comprehensive
search, independent duplicate assessment of eligibility,
and the use of the GRADE approach to assessing quality
of evidence of effect including independent duplicate as-
sessment of risk of bias, precision, consistency, directness,
and publication bias. Our protocol represents a model for
systematic review methods. Our results are likely to be
limited by limitations in the primary studies.
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